PMID- 28349442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 8
IP  - 3
DP  - 2017 Jun
TI  - Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese 
      Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, 
      Single-Arm Study.
PG  - 611-621
LID - 10.1007/s13300-017-0247-6 [doi]
AB  - INTRODUCTION: There is relatively little data from China on the efficacy and 
      safety of adding prandial insulin to basal insulin plus oral antidiabetic drugs 
      (OADs) in people with poorly controlled type 2 diabetes mellitus (T2DM). This 
      study assessed the efficacy and safety of basal insulin dose optimization 
      followed by the addition of prandial insulin in Chinese people with T2DM 
      achieving suboptimal glycemic control with basal insulin and OADs. METHODS: In 
      this open-label, single-arm study, adults with T2DM receiving basal insulin plus 
      OADs underwent insulin dose optimization for 12 weeks. At week 12, subjects who 
      achieved fasting blood glucose (FBG) </=6.5 mmol/L but not HbA1c </=7% added one 
      injection of prandial insulin at the main meal for an additional 24 weeks. 
      Endpoints included mean HbA1c, the achievement rate of HbA1c </=7%, hypoglycemia, 
      and other adverse events (AEs). RESULTS: A total of 120 subjects underwent basal 
      insulin optimization; At week 12, 110 study subjects achieved FBG </=6.5 mmol/L, of 
      whom 66 did not achieve HbA1c </=7% and therefore initiated prandial insulin. Three 
      patients discontinued prandial insulin due to dissatisfaction with treatment 
      outcome (n = 1), accidental injury (n = 1), or personal reasons (n = 1). After 
      24 weeks of basal-plus treatment, mean HbA1c significantly decreased (8.06% to 
      7.17%; p < 0.001), 65.1% of subjects achieved HbA1c </=7%, there was no change in 
      FBG (6.23-6.20 mmol/L; p = 0.118), and mean post-prandial blood glucose decreased 
      (13.17-10.14 mmol/L; p < 0.001). During basal-plus treatment, three individuals 
      experienced hypoglycemia, and no significant change in the mean subject weight 
      was observed (73.2 vs. 73.3 kg; p = 0.379). CONCLUSIONS: In people with T2DM who 
      are achieving suboptimal glycemic control with basal insulin plus OADs, basal 
      insulin dose optimization followed by the addition of prandial insulin improves 
      glycemic control, is well tolerated, and is associated with a low incidence of 
      hypoglycemia.
FAU - Jin, Yujing
AU  - Jin Y
AD  - Tianjin Medical University General Hospital, Tianjin, 300052, China.
FAU - Sun, Xiaowei
AU  - Sun X
AD  - Tianjin Medical University General Hospital, Tianjin, 300052, China.
FAU - Zhao, Xichen
AU  - Zhao X
AD  - Tianjin Medical University General Hospital, Tianjin, 300052, China.
FAU - Zhu, Tiehong
AU  - Zhu T
AD  - Tianjin Medical University General Hospital, Tianjin, 300052, China. 
      zhutiehong@tmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20170327
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
EIN - Diabetes Ther. 2017 Jun;8(3):623-624. PMID: 28401453
PMC - PMC5446374
OTO - NOTNLM
OT  - Basal insulin
OT  - HbA1c
OT  - Insulin glargine
OT  - Prandial insulin
OT  - Type 2 diabetes
EDAT- 2017/03/30 06:00
MHDA- 2017/03/30 06:01
PMCR- 2017/03/27
CRDT- 2017/03/29 06:00
PHST- 2017/02/21 00:00 [received]
PHST- 2017/03/30 06:00 [pubmed]
PHST- 2017/03/30 06:01 [medline]
PHST- 2017/03/29 06:00 [entrez]
PHST- 2017/03/27 00:00 [pmc-release]
AID - 10.1007/s13300-017-0247-6 [pii]
AID - 247 [pii]
AID - 10.1007/s13300-017-0247-6 [doi]
PST - ppublish
SO  - Diabetes Ther. 2017 Jun;8(3):611-621. doi: 10.1007/s13300-017-0247-6. Epub 2017 
      Mar 27.